Circadian regulation of DNA excision repair: Implications for chrono-chemotherapy

Cell Cycle

Volumn 8, Issue 11, 2009, Pages 1665-1667

  Kang, Tae Hong ^a   Sancar, Aziz ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Circadian rhythm; Cisplatin; Nucleotide excision repair; XPA

Indexed keywords

CARBOPLATIN; CISPLATIN; CRYPTOCHROME; OXALIPLATIN; PER2 PROTEIN; PROTEIN BMAL1; TRANSCRIPTION FACTOR CLOCK; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONOTHERAPY; CIRCADIAN RHYTHM; EXCISION REPAIR; HUMAN; KIDNEY FAILURE; METASTASIS; MONOTHERAPY; NONHUMAN; SHORT SURVEY; TARGET CELL DESTRUCTION; TESTIS CANCER;

MAMMALIA;

EID: 66749163054     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.11.8707     Document Type: Short Survey

References (22)

1. Hastings MH, Maywood ES, O'Neill JS. Cellular circadian pacemaking and the role of cytosolic rhythms. Curr Biol 2008; 18:805-815
2. Sancar A. The intelligent clock and the Rube Goldberg clock. Nat Struct Mol Biol 2008; 15:12-15
3. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 2007; 316:900-904 (Pubitemid 46764282)
4. Godinho SI, Maywood ES, Shaw L, Tucci V, Barnard AR, Busino L, et al. The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science 2007; 316:897-900. (Pubitemid 46764281)
5. Reischl S, Vanselow K, Westermark PO, Thierfelder N, Maier B, Herzel H, et al. Beta-TrCP1-mediated degradation of PERIOD2 is essential for circadian dynamics. J Biol Rhythms 2007; 22:375-386 (Pubitemid 47507053)
6. Shirogane T, Jin J, Ang XL, Harper JW. SCFbeta-TRCP controls clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian period-1 (Per1) protein. J Biol Chem 2005; 280:26863-26872 (Pubitemid 41040720)
7. Siepka SM, Yoo SH, Park J, Song W, Kumar V, Hu Y, et al. Circadian mutant Overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. Cell 2007; 129:1011-1023 (Pubitemid 46802705)
8. Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci USA 2009; 106:2864-2867
9. Reardon JT, Sancar A. Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 2005; 79:183-235.
10. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8:193-204.
11. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23. (Pubitemid 46137553)
12. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110:352-361 (Pubitemid 38649885)
13. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63:1311-1316 (Pubitemid 36348710)
14. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60:1305-1313
15. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9:273-276 (Pubitemid 29139312)
16. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299:672-684
17. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-584
18. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23:460-464 (Pubitemid 37176691)
19. Hrushesky WJ. Circadian timing of cancer chemotherapy. Science 1985; 228:73-75 (Pubitemid 15122991)
20. Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzi V, Spalletta B, et al. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 2007; 59:613-620 (Pubitemid 46295125)
21. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21:3808-3813 (Pubitemid 46606236)
22. Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993; 16:494-496 (Pubitemid 24004100)